4.4.23-Health-Replay-Holdings

MATT MULVEY: I'd like to thank everybody for inviting us to talk today and to give this pitch. So, we're called Replay. The reason we're called Replay, it's taken from a line by the evolutionary theorist Steven Jay Gould, who said that if you were to replay the tape of time, you would come out with a completely different outcome, meaning that what we see in nature today is really just a drive from chance and randomness, and there's so much more potential for engineering and for having biological outputs than we see today.

And so what we hope to do with Replay is to build an enduring company that is able to reprogram human biology first at the gene therapy and cell therapy levels and then ultimately up into the organismal level.

So the company is co-founded by four people, Adrian Wilson and Lachlan MacKinnon, David Knipe and Professor Ron Weiss from MIT. Adrian basically ran oncology for Bristol-Myers Squibb and Pfizer. Lachlan is a very accomplished ex-venture capitalist and Dr. Knipe is the head of-- He's perhaps the world leading expert in virology with a focus on HSV, which is our gene therapy vector system and Ron Weiss of course, is known as the father of synthetic biology and head of synthetic biology here at MIT.

We have a very established management team. I am CTO. My background is in HSV molecular genetic design and product development. I've got mostly in the oncolytic space and I'm leading the development of our HSV based gene therapy platform. The other members of the management team are very well accomplished and really know what they're doing.

Our board of directors is-- We completed a $55 million round last year, a seed round driven by KKR, which is known as the private equity group that kind of pioneered the new hub and spoke business model in biotech of which we hope to perfect with our business model. And I am contractually obligated to say that we have the best SAB ever assembled.

[LAUGHTER]

We have two Nobel laureates. We have the father of modern gene therapy, Fraser Wright, who did spark and we have Carl June and we'll get into that a little bit later. Carl June is known as the father of car T-cell therapy.

So what we do at Replay is we separate product development from platform development using the hub and spoke model. Our platforms are derived-- We basically have three to six platforms depending on how you think about it using IP that we've licensed in from MIT, Harvard, and other very renowned places.

And we work with these platforms in the hub. The general goal here is to first hedge the risk of startup by having multiple platforms that we stand up simultaneously. So if one falls down another one will be successful and we can move to the next level. But also, these platforms are carefully chosen in that the different modules from each of them can be combined with modules from the other ones to do things that no one else can do.

When we have a product that is headed towards the clinic we can put it into our product company and incentivize thought leaders for a disease indication and technology indication to really drive the value of that product. This is our current pipeline split between an almost to clinic cell therapy platform in a product company called Siena and then we have several HSV gene therapy product companies with various targets that we're going after.

What we hope to achieve over the next couple of years is six INDs and at least two study readouts and perhaps a first in human registration. What we're getting a lot of attention for now is we have exclusive worldwide license to the first TCR NK platform. This is coming from ND Anderson from the lab of Katy Rezvani who is kind of known as the Carl June of NKs.

And she showed that if she takes an NK and puts in Carl Jones CD19 car she can get equivalent responses to car T-cells--

[PHONE RINGING]

Sorry. But with a much better safety profile with similar durability. And our platform is basically that clinically successful platform of car NKs just swapping out the car with a TCR. And our HSV gene therapy platform is built for the next generation of gene therapy and reprogramming biology in that we can-- The current standard right now is AAV that can deliver about five KB. Our existing version one system can deliver 40 KB and are almost finished version two system can deliver up 150 KB.

I'll skip this. And so, our partnerships, we're definitely looking for-- As a company that has a very seasoned management team we're looking for clinical assets that we can license in that complement our activities. We're looking to partner our technologies that would complement our portfolio. And of course, we'd love to talk to people who have common interests and share our vision. Thank you.